Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 7/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31645422 | 0.93 | KDM4E (0.38) | ROCK2USP30KDM4EMAPTTHRB | |
| SCHEMBL31645936 | 0.93 | NAMPT (0.37) | ROCK2USP30KDM4EMAPTTHRB | |
| SCHEMBL31646257 | 0.93 | DDB1 (0.40) | ROCK2KDM4EMAPTTHRBDDB1 | |
| SCHEMBL31645675 | 0.91 | ROCK2 (0.39) | ROCK2KDM4EMAPTTHRBDDB1 | |
| SCHEMBL31645667 | 0.88 | KDM4E (0.38) | ROCK2KDM4EMAPTTHRBDDB1 | |
| SCHEMBL31646142 | 0.88 | HPGD (0.40) | ROCK2KDM4EMAPTTHRBDDB1 | |
| SCHEMBL31329667 | 0.85 | EPHX1 (0.40) | ROCK2DDB1CRBNNAMPTGPR119 | |
| SCHEMBL31645462 | 0.84 | ROCK2 (0.38) | ROCK2KDM4EMAPTTHRBDDB1 | |
| SCHEMBL22941610 | 0.80 | ALDH1A1 (0.40) | ROCK2KDM4EMAPTTHRBDDB1 | |
| SCHEMBL31081976 | 0.80 | DDB1 (0.41) | KDM4EMAPTTHRBDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | WRN, RECQL, BLM | ROCK2 2856/4885USP30 633/4885KDM4E 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.